There is growing evidence that social drivers of health can impact health outcomes in dermatology patients, according to a session at the 2025 American Academy of Dermatology Meeting, held in Orlando. Drivers include a patient’s economic stability, education and healthcare access.
Rebecca Vasquez, M.D., FAAD, said that while there is not yet enough data to support success stories, she has seen firsthand the ways addressing social drivers of health has impacted her patients.
“I think that these things take time, and learning how to gather meaningful data that these sort of programs are making tangible differences,” Vasquez said in an interview conducted at the meeting. “I can tell you, anecdotally, when I'm able to provide a patient who has no insurance with dermatologic care, and I see people come in for skin cancer, and we're able to provide affordable treatment for that, those are tangible differences.”
Vasquez is speaking at four AAD 2025 sessions this year. Her first session was yesterday afternoon and was called Bridging the Gap: Addressing Social Determinants of Health to Decrease Health Disparities in Dermatology.
Social Drivers of Health Success Stories in Dermatology | AAD 2025
Peter Wehrwein, Managing Editor
Rebecca Vasquez, M.D., FAAD, said that while there is not enough data to support success stories yet, she has seen firsthand the ways addressing social drivers of health has impacted her patients.
There is growing evidence that social drivers of health can impact health outcomes in dermatology patients, according to a session at the 2025 American Academy of Dermatology Meeting, held in Orlando. Drivers include a patient’s economic stability, education and healthcare access.
Rebecca Vasquez, M.D., FAAD, said that while there is not yet enough data to support success stories, she has seen firsthand the ways addressing social drivers of health has impacted her patients.
“I think that these things take time, and learning how to gather meaningful data that these sort of programs are making tangible differences,” Vasquez said in an interview conducted at the meeting. “I can tell you, anecdotally, when I'm able to provide a patient who has no insurance with dermatologic care, and I see people come in for skin cancer, and we're able to provide affordable treatment for that, those are tangible differences.”
Vasquez is speaking at four AAD 2025 sessions this year. Her first session was yesterday afternoon and was called Bridging the Gap: Addressing Social Determinants of Health to Decrease Health Disparities in Dermatology.
Analysis Finds Opzelura Not Associated with Cancer or Cardiovascular Events
In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated to cream strength, and generally reflective of background rates in the broader population with atopic dermatitis.
Read More
Positive Results For Remibrutinib May Redraw the Lines For Who Takes Care of Patients With Chronic Spontaneous Urticaria
The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the American Academy of Dermatology.
Read More
The 2025 AAD Meeting is Underway | AAD 2025
Read More
Annual AAD Meeting in San Diego Wraps Up | AAD 2024
Almost 20,000 dermatologists attended the annual meeting this weekend at the San Diego Convention Center.
Read More
Positive Results for JAK1 Inhibitor Povorcitinib Reported in Late Breaker | AAD 2024
The Incyte drug is headed for assessment in a phase 3 trial.
Read More
William Shatner Discusses Stage 4 Melanoma Diagnosis, Treatment | AAD 2024
The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.
Read More
Analysis Finds Opzelura Not Associated with Cancer or Cardiovascular Events
In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated to cream strength, and generally reflective of background rates in the broader population with atopic dermatitis.
Read More
Positive Results For Remibrutinib May Redraw the Lines For Who Takes Care of Patients With Chronic Spontaneous Urticaria
The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the American Academy of Dermatology.
Read More
The 2025 AAD Meeting is Underway | AAD 2025
Read More
Annual AAD Meeting in San Diego Wraps Up | AAD 2024
Almost 20,000 dermatologists attended the annual meeting this weekend at the San Diego Convention Center.
Read More
Positive Results for JAK1 Inhibitor Povorcitinib Reported in Late Breaker | AAD 2024
The Incyte drug is headed for assessment in a phase 3 trial.
Read More
William Shatner Discusses Stage 4 Melanoma Diagnosis, Treatment | AAD 2024
The 92-year-old "Star Trek" star said the skin cancer was treated surgically and with immunotherapy. It was apparently the first time he had discussed his melanoma in public.
Read More